AC
TEVA icon

Aaron Cowen’s Teva Pharmaceuticals TEVA Stock Holding History

Aaron Cowen’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-575,000
Closed -$35.8M – 38
2015
Q1 		$35.8M Buy
+575,000
New +$33.4M 2.14% 20

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Aaron Cowen's TEVA Position: Q4 2024 in Review

Aaron Cowen sold out of Teva Pharmaceuticals (TEVA) in Q4 2024, closing a stake of 268,100 shares — an estimated $4.83M sold.

Aaron Cowen first reported a position in TEVA in Q1 2014 and held it in 8 quarters. The position peaked at $93.7M in Q4 2015. 584 funds tracked by Wall St. Rank hold TEVA as of Q4 2024.

  • Aaron Cowen reported no remaining Teva Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Aaron Cowen sold 268,100 Teva Pharmaceuticals shares in Q4 2024, an estimated $4.83M.
  • Aaron Cowen first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 8 quarters.
  • Aaron Cowen's Teva Pharmaceuticals position peaked at $93.7M in Q4 2015.
  • 584 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2024.

Based on Suvretta Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.